The ERACE-PA Global Surveillance Program: Ceftolozane/tazobactam and Ceftazidime/avibactam in vitro Activity against a Global Collection of Carbapenem-resistant Pseudomonas aeruginosa

Abstract

The cephalosporin-β-lactamase-inhibitor-combinations, ceftolozane/tazobactam and ceftazidime/avibactam, have revolutionized treatment of carbapenem-resistant Pseudomonas aeruginosa (CR-PA). A contemporary assessment of their in vitro potency against a global CR-PA collection and an assessment of carbapenemase diversity are warranted. Isolates determined as CR-PA by the submitting site were collected from 2019-2021 (17 centers in 12 countries) during the ERACE-PA Global Surveillance Program. Broth microdilution MICs were assessed per CLSI standards for ceftolozane/tazobactam, ceftazidime/avibactam, ceftazidime, and cefepime. Phenotypic carbapenemase testing was conducted (modified carbapenem inactivation method (mCIM)). mCIM positive isolates underwent genotypic carbapenemase testing using the CarbaR, the CarbaR NxG, or whole genome sequencing. The MIC_50/90 was reported as well as percent susceptible (CLSI and EUCAST interpretation). Of the 807 isolates, 265 (33%) tested carbapenemase-positive phenotypically. Of these, 228 (86%) were genotypically positive for a carbapenemase with the most common being VIM followed by GES. In the entire cohort of CR-PA, ceftolozane/tazobactam and ceftazidime/avibactam had MIC_50/90 values of 2/ > 64 and 4/64 mg/L, respectively. Ceftazidime/avibactam was the most active agent with 72% susceptibility per CLSI compared with 63% for ceftolozane/tazobactam. For comparison, 46% of CR-PA were susceptible to ceftazidime and cefepime. Against carbapenemase-negative isolates, 88 and 91% of isolates were susceptible to ceftolozane/tazobactam and ceftazidime/avibactam, respectively. Ceftolozane/tazobactam and ceftazidime/avibactam remained highly active against carbapenem-resistant P. aeruginosa, particularly in the absence of carbapenemases. The contemporary ERACE-PA Global Program cohort with 33% carbapenemase positivity including diverse enzymology will be useful to assess therapeutic options in these clinically challenging organisms with limited therapies.

Keywords: Carbapenem-resistant P. aeruginosa; Carbapenemase; Ceftazidime/avibactam; Ceftolozane/tazobactam.

Fig. 1

a MIC distribution of tested agents in the entire cohort. Ceftolozane/tazobactam: MIC_50/90 2/ > 64 mg/L, 63% susceptible; Ceftazidime/avibactam: MIC_50/90 4/64 mg/L, 72% susceptible. Ceftazidime: MIC_50/90 16/ > 64 mg/L, 46% susceptible; cefepime MIC_50/90 16/ > 64, 46% susceptible. b. MIC distribution of tested agents in the phenotypically carbapenemase negative isolates. Ceftolozane/tazobactam: MIC_50/90 1/8 mg/L, 88% susceptible; Ceftazidime/avibactam: MIC_50/90 2/8 mg/L, 91% susceptible. Ceftazidime: MIC_50/90 4/ > 64 mg/L, 65% susceptible; cefepime MIC_50/90 8/64, 63% susceptible